Sonic Healthcare's FY26: Record Revenue, a U.S. Overhaul, and a Digital Bet
Revenue up 13% and EBITDA up 11%, but the strategic focus is on the U.S. operating review, a digital transformation, and disciplined capital management.
SHL.AX · Earnings Call · 2026-08-19
Solid FY26 Results, But the Real News is the Strategy
Sonic Healthcare delivered a strong FY26, with total revenue growing 13% to AUD 10.867 billion and EBITDA up 11% to AUD 1.933 billion. Net profit after tax rose 17% to AUD 621 million, and EPS gained 14% to AUD 1.26. As CEO Jim Newcombe put it, “We delivered solid financial results in FY 2026, achieving our EBITDA guidance for the year on an underlying basis.” — Jim Newcombe, Chief Executive Officer and Managing Director · 2026-08-19 But beyond the headline numbers, the company is clearly repositioning for the next phase—through acquisitions, a sweeping digital initiative, and a more aggressive approach to capital returns.
The most significant strategic moves include the completion of the LADR acquisition in Germany and the U.S. Ciro Diagnostics purchase, both aimed at boosting Advanced diagnostics capabilities. The company also launched a major digital transformation, with an annual investment of approximately AUD 30 million over three years to modernize its global IT infrastructure. According to Jim,
This company-wide transformation represents a step change in our ability to deliver better outcomes for doctors, patients, and shareholders in an increasingly digital world.
The U.S. Operating Review Takes Center Stage
One of the clearest shifts is the focus on the operating review of the U.S. business. Management has already rationalized nine anatomical pathology practices, cut corporate headcount by 10%, and identified AUD 25–30 million in earnings improvements for FY27. As Newcombe stated in the Q&A, “Our focus has been and continues to be on the operating review.” — Jim Newcombe, Chief Executive Officer and Managing Director · 2026-08-19 The company is not just cutting costs—it's investing in growth areas like dermatopathology and advanced diagnostics, which delivered 16% organic growth in the year.
This is a marked evolution from prior quarters. In February 2026, CFO Chris Wilks had already hinted at the capital management angle, noting about the sale-and-leaseback of the Brisbane lab: “It comes down to just a broader capital management strategy with properties like this.” — Christopher Wilks, Chief Financial Officer · 2026-02-18 That transaction, completed in June, generated a AUD 107 million gain and underscores a new discipline around capital management. With the final dividend raised modestly and buybacks now explicitly on the priority list, the company is signaling a more shareholder-friendly approach.
FY27 Guidance: Strong Growth, But With Known Headwinds
For FY27, Sonic expects constant-currency EBITDA in the range of AUD 1.95–2.03 billion, excluding AUD 30 million of IT transformation costs. CFO Chris Wilks guided: “On a constant currency basis, we expect EBITDA to be within the range of AUD 1.95 billion to AUD 2.03 billion.” — Chris Wilks, Chief Financial Officer · 2026-08-19 This implies only low- to mid-single-digit growth, reflecting two specific headwinds: Swiss fee cuts (CHF 20 million revenue impact) and the extended integration timeline of the U.K.'s HWE contract. Management expects the HWE contract to reach planned margins only by H2 FY28, a delay that weighs on near-term profitability.
While the U.S. and U.K. will be margin-dilutive in the near term, the company sees long-term upside from synergies and operational leverage. In Australia, private billing initiatives and strong specialist referrals drove 5% organic growth, and the company expects continued momentum. The prior U.S. commentary from August 2025, where Paul Alexander described July growth as "a bit of a green shoot" (“it is a bit of a green shoot” — Paul J. Alexander, Deputy Chief Financial Officer · 2025-08-21), now looks prescient—though the operating review is still a work in progress.
What It Means for Investors
Sonic is at an inflection point. The FY26 results demonstrate the resilience of its diversified model, but the strategic bets on digital transformation and U.S. turnaround are still in early innings. The company is balancing growth investments with capital returns, and the market will be watching execution closely. With a AUD 9.1 billion market cap and a strong franchise, this is a company that's investing for the long term, even if the immediate earnings outlook is muted by known regulatory and contract timing issues.